223 completed, 63 recruiting, 34 unknown, 31 terminated. 116 Phase 2, 73 Not applicable, 62 Phase 3, 35 Phase 1, 33 Phase 4.
Follow Skin Diseases, Bacterial: new trials by email Literature Review of Skin Diseases, Bacterial trials Research Report on Skin Diseases, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 186 | 2026-11-13 | 2026-10-20 | |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Olatorepatide, Placebo - Hidradenitis Suppurativa | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 300 | 2026-10-30 | 2026-09-21 |
| A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 34 | 2026-10-30 | 2026-09-21 | |
| A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS LOU064, Placebo - Hidradenitis Suppurativa | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-10-15 | 2026-10-16 |
| Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis Atopic Dermatitis (AD), Scabies | Not yet recruiting | Istanbul Medeniyet University | 51 | 2026-10-01 | 2026-09-15 | |
| Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases Psoriasis, Eczema/Atopic Dermatitis | Not yet recruiting | Medisch Spectrum Twente | 1000 | 2026-10-01 | 2026-09-04 | |
| Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | University of Massachusetts, Worcester | 40 | 2026-10-01 | 2026-09-10 |
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa Soquelitinib - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | 25 | 2026-09-17 | 2026-10-15 |
| Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Harrison Dermatology | 10 | 2026-09-10 | 2026-10-13 |
| The Safety and Efficacy of Roflumilast Foam in HS Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 20 | 2026-09-01 | 2026-07-09 |
| Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center Tonsillitis Acute, Pneumonia - Bacterial | Not yet recruiting | University Hospital, Montpellier | 191 | 2026-09-01 | 2026-07-17 | |
| Mediterranean Dietary Intervention for HS Mediterranean Diet Counseling, Mediterranean Food Support - Hidradenitis Suppurativa | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 30 | 2026-09-01 | 2026-09-02 |
| An Observational Study of Patients With Dermatologic Disease Vitiligo, Atopic Dermatitis | Not yet recruiting | Target PharmaSolutions, Inc. | 2000000 | 2026-09-01 | 2026-09-10 | |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Spyre Therapeutics, Inc. | 150 | 2026-09-01 | 2026-10-19 |
| Urinary Bladder Matrix (UBM) Registry Urinary Bladder Matrix (UBM) Products - Tissue Repair, Soft Tissue Reconstruction | Not yet recruiting | Integra LifeSciences Corporation | 300 | 2026-08-31 | 2026-09-04 | |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa ORKA-002, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | 200 | 2026-08-21 | 2026-09-24 |
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Remibrutinib - Hidradenitis Suppurativa | Phase 3 | Recruiting | Novartis Pharmaceuticals | 710 | 2026-07-10 | 2026-10-13 |
| Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa Nd:YAG Laser, Alexandrite Laser - Hidradenitis Suppurativa (HS) | Not applicable | Not yet recruiting | Geisinger Clinic | 21 | 2026-07-01 | 2026-04-28 |
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa Secukinumab - Hidradenitis Suppurativa (HS) | Phase 4 | Recruiting | Novartis Pharmaceuticals | 36 | 2026-06-01 | 2026-09-09 |
Showing 20 of 414. Sign in to see all of them.
Hidradenitis Suppurativa (280) · Impetigo (30) · Staphylococcal Skin Infections (30) · Abscess (27) · Cellulitis (27) · Hidradenitis (27) · Dermatitis, Atopic (24) · Skin Diseases (23) · Psoriasis (22) · Staphylococcal Infections (19) · Yaws (16) · Skin Diseases, Infectious (15) · Furunculosis (14) · Bacterial Infections (12)
Bacterial Infections and Mycoses (413) · Skin and Connective Tissue Diseases (412) · Bacterial Infections (402) · Infections (402) · Skin Diseases, Infectious (399) · Skin Diseases (391) · Suppuration (312) · Sweat Gland Diseases (273) · Hidradenitis (253) · Gram-Positive Bacterial Infections (95) · Pathological Conditions, Signs and Symptoms (80) · Pathologic Processes (75) · Staphylococcal Infections (57) · Inflammation (51)
Adalimumab (16) · Vancomycin (14) · secukinumab (14) · Linezolid (9) · Azithromycin (8) · Mupirocin (8) · bimekizumab (7) · Aztreonam (5) · Clindamycin (5) · Doxycycline (5) · chlorhexidine gluconate (5) · remibrutinib (5) · sonelokimab (5) · Blood Specimen Collection (4) · Daptomycin (4)
Novartis Pharmaceuticals (21) · AbbVie (16) · Incyte Corporation (12) · Henry Ford Health System (7) · Basilea Pharmaceutica (6) · UCB Biopharma SRL (6) · University of Miami (6) · Assistance Publique - Hôpitaux de Paris (5) · GlaxoSmithKline (5) · Lihir Medical Centre (5) · Montefiore Medical Center (5) · MoonLake Immunotherapeutics AG (5) · Boehringer Ingelheim (4) · Florida Academic Dermatology Centers (4) · Janssen Research & Development, LLC (4)
United States (208) · Germany (72) · Canada (67) · France (56) · Spain (54) · Poland (48) · Netherlands (43) · Australia (38) · Italy (35) · Greece (34) · Bulgaria (28) · Belgium (26) · Denmark (26) · United Kingdom (25) · Czechia (24)
Hadar Lev-Tov, MD (5) · Christopher J Sayed, MD (3) · John W Frew, MD (3)
PMID 27518661, PMID 29380251, PMID 31604104, PMID 36746171, PMID 41248770, PMID 42525209, PMID 18444791, PMID 19095213, PMID 20695801, PMID 21115456, PMID 22236226, PMID 22416054, PMID 23247938, PMID 28630189, PMID 30075748, PMID 30349845, PMID 30365584, PMID 30597021, PMID 30716446, PMID 32460374, PMID 34252397, PMID 34741280, PMID 34922058, PMID 34978076, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 10798549, PMID 11448564, PMID 12140476, PMID 12145720, PMID 14557966, PMID 14632813, PMID 16918566, PMID 17192170, PMID 17587838, PMID 18225981, PMID 19036028, PMID 19146007, PMID 19185954
2025 (9), 2023 (8), 2018 (5), 2019 (3), 2008 (2), 2014 (2), 2004 (1), 2015 (1), 2017 (1), K08AR080844 (1), KL2RR031974 (1), R01DK135645 (1), R01NR013888 (1), R33AR077495 (1), R61AR087105 (1)